GDTC Stock Summary and Trading Ideas (Cytomed Therapeutics Limited - | NASDAQ:GDTC)

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Cytomed Therapeutics Limited - trades on the NASDAQ stock market under the symbol GDTC.

As of December 26, 2025, GDTC stock price declined to $1.53 with 12,237 million shares trading.

GDTC has a beta of 0.04, meaning it tends to be less sensitive to market movements. GDTC has a correlation of 0.00 to the broad based SPY ETF.

GDTC has a market cap of $17.95 million. This is considered a Sub-Micro Cap stock.

GDTC has underperformed the market in the last year with a price return of -45.3% while the SPY ETF gained +16.0%. GDTC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.1% and -7.8%, respectively, while the SPY returned +4.6% and +1.5%, respectively.

GDTC support price is $1.43 and resistance is $1.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDTC shares will trade within this expected range on the day.